Document is current
Any future updates will be listed below
-
Authors
Drouard, Gabin
Wang, Zhiyang
Heikkinen, Aino
Foraster, Maria
Julvez, Jordi
Kanninen, Katja M.
van Kamp, Irene
Pirinen, Matti
Ollikainen, Miina
Kaprio, Jaakko
-
Funding
Funding for this research was provided by:
Research Council of Finland (328685, 307339, 297908, 251316, 100499, 205585, 118555, 141054, 264146, 308248)
Sigrid Juselius Foundation
Centre of Excellence in Complex Disease Genetics (312073, 336823, 352792)
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 5 September 2024
First Online: 11 September 2024
Competing interests
: The authors declare no competing interests.
: The ethics committee of the Department of Public Health of the University of Helsinki and the Institutional Review Board of Indiana University approved the FinnTwin12 study protocol from the start of the cohort. The ethical approval of the ethics committee of the Helsinki University Central Hospital District (HUS) is the most recent and covers the most recent data collection (wave 4) (HUS/2226/2021). The HUS reviews the study annually, and 2023’s statement is number 4/2023, dated 1 February 2023. All participants and their parents/legal guardians gave informed written consent to participate in the study. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
